6-145735336-G-T

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2

The NM_005670.4(EPM2A):​c.163C>A​(p.Gln55Lys) variant causes a missense change. The variant allele was found at a frequency of 0.0186 in 1,383,174 control chromosomes in the GnomAD database, including 296 homozygotes. In-silico tool predicts a benign outcome for this variant. 14/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. Q55P) has been classified as Uncertain significance.

Frequency

Genomes: 𝑓 0.012 ( 9 hom., cov: 32)
Exomes 𝑓: 0.019 ( 287 hom. )

Consequence

EPM2A
NM_005670.4 missense

Scores

1
3
13

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:8O:1

Conservation

PhyloP100: 4.35

Publications

11 publications found
Variant links:
Genes affected
EPM2A (HGNC:3413): (EPM2A glucan phosphatase, laforin) This gene encodes a dual-specificity phosphatase and may be involved in the regulation of glycogen metabolism. The protein acts on complex carbohydrates to prevent glycogen hyperphosphorylation, thus avoiding the formation of insoluble aggregates. Loss-of-function mutations in this gene have been associated with Lafora disease, a rare, adult-onset recessive neurodegenerative disease, which results in myoclonus epilepsy and usually results in death several years after the onset of symptoms. The disease is characterized by the accumulation of insoluble particles called Lafora bodies, which are derived from glycogen. [provided by RefSeq, Jan 2018]
EPM2A-DT (HGNC:48990): (EPM2A divergent transcript)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.0077129304).
BP6
Variant 6-145735336-G-T is Benign according to our data. Variant chr6-145735336-G-T is described in ClinVar as Benign. ClinVar VariationId is 129003.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BS1
Variant frequency is greater than expected in population nfe. GnomAd4 allele frequency = 0.0117 (1763/150262) while in subpopulation NFE AF = 0.0186 (1253/67332). AF 95% confidence interval is 0.0178. There are 9 homozygotes in GnomAd4. There are 812 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position passed quality control check.
BS2
High Homozygotes in GnomAd4 at 9 AR gene

Variant Effect in Transcripts

ACMG analysis was done for transcript: NM_005670.4. You can select a different transcript below to see updated ACMG assignments.

RefSeq Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
EPM2A
NM_005670.4
MANE Select
c.163C>Ap.Gln55Lys
missense
Exon 1 of 4NP_005661.1
EPM2A
NM_001018041.2
c.163C>Ap.Gln55Lys
missense
Exon 1 of 5NP_001018051.1
EPM2A
NM_001368130.1
c.163C>Ap.Gln55Lys
missense
Exon 1 of 3NP_001355059.1

Ensembl Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
EPM2A
ENST00000367519.9
TSL:1 MANE Select
c.163C>Ap.Gln55Lys
missense
Exon 1 of 4ENSP00000356489.3
EPM2A
ENST00000435470.2
TSL:1
c.163C>Ap.Gln55Lys
missense
Exon 1 of 5ENSP00000405913.2
EPM2A
ENST00000638262.1
TSL:1
c.163C>Ap.Gln55Lys
missense
Exon 1 of 3ENSP00000492876.1

Frequencies

GnomAD3 genomes
AF:
0.0117
AC:
1764
AN:
150154
Hom.:
9
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00381
Gnomad AMI
AF:
0.0242
Gnomad AMR
AF:
0.00748
Gnomad ASJ
AF:
0.00145
Gnomad EAS
AF:
0.000196
Gnomad SAS
AF:
0.00520
Gnomad FIN
AF:
0.0173
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0186
Gnomad OTH
AF:
0.00774
GnomAD2 exomes
AF:
0.0123
AC:
957
AN:
77612
AF XY:
0.0124
show subpopulations
Gnomad AFR exome
AF:
0.00222
Gnomad AMR exome
AF:
0.00561
Gnomad ASJ exome
AF:
0.00169
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.0227
Gnomad NFE exome
AF:
0.0209
Gnomad OTH exome
AF:
0.0109
GnomAD4 exome
AF:
0.0194
AC:
23941
AN:
1232912
Hom.:
287
Cov.:
30
AF XY:
0.0191
AC XY:
11586
AN XY:
607676
show subpopulations
African (AFR)
AF:
0.00261
AC:
63
AN:
24162
American (AMR)
AF:
0.00667
AC:
156
AN:
23396
Ashkenazi Jewish (ASJ)
AF:
0.00189
AC:
37
AN:
19586
East Asian (EAS)
AF:
0.000220
AC:
5
AN:
22680
South Asian (SAS)
AF:
0.00729
AC:
491
AN:
67368
European-Finnish (FIN)
AF:
0.0219
AC:
657
AN:
29992
Middle Eastern (MID)
AF:
0.00481
AC:
18
AN:
3746
European-Non Finnish (NFE)
AF:
0.0220
AC:
21807
AN:
993364
Other (OTH)
AF:
0.0145
AC:
707
AN:
48618
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.508
Heterozygous variant carriers
0
1277
2554
3832
5109
6386
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
908
1816
2724
3632
4540
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0117
AC:
1763
AN:
150262
Hom.:
9
Cov.:
32
AF XY:
0.0111
AC XY:
812
AN XY:
73394
show subpopulations
African (AFR)
AF:
0.00380
AC:
157
AN:
41328
American (AMR)
AF:
0.00747
AC:
113
AN:
15120
Ashkenazi Jewish (ASJ)
AF:
0.00145
AC:
5
AN:
3440
East Asian (EAS)
AF:
0.000197
AC:
1
AN:
5082
South Asian (SAS)
AF:
0.00521
AC:
25
AN:
4802
European-Finnish (FIN)
AF:
0.0173
AC:
171
AN:
9870
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
290
European-Non Finnish (NFE)
AF:
0.0186
AC:
1253
AN:
67332
Other (OTH)
AF:
0.00766
AC:
16
AN:
2088
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.504
Heterozygous variant carriers
0
91
183
274
366
457
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
20
40
60
80
100
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00364
Hom.:
3
Bravo
AF:
0.0112
ExAC
AF:
0.00768
AC:
326

ClinVar

Significance: Benign
Submissions summary: Benign:8Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:4
Jun 19, 2012
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.

Sep 16, 2024
Athena Diagnostics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Apr 09, 2018
Eurofins Ntd Llc (ga)
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Sep 19, 2015
Genetic Services Laboratory, University of Chicago
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

not provided Benign:2
Aug 09, 2017
Mayo Clinic Laboratories, Mayo Clinic
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

Feb 01, 2023
CeGaT Center for Human Genetics Tuebingen
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

EPM2A: PP3, BS1, BS2

Inborn genetic diseases Benign:1
Feb 21, 2017
Ambry Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.

Progressive myoclonic epilepsy Benign:1
Feb 04, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Lafora disease Other:1
GeneReviews
Significance:not provided
Review Status:no classification provided
Collection Method:literature only

Computational scores

Source: dbNSFP v4.9

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.16
BayesDel_addAF
Benign
-0.24
T
BayesDel_noAF
Benign
-0.10
CADD
Benign
18
DANN
Benign
0.93
DEOGEN2
Uncertain
0.45
T
Eigen
Benign
-0.27
Eigen_PC
Benign
-0.21
FATHMM_MKL
Uncertain
0.92
D
LIST_S2
Benign
0.66
T
MetaRNN
Benign
0.0077
T
MetaSVM
Uncertain
0.14
D
MutationAssessor
Benign
1.7
L
PhyloP100
4.4
PrimateAI
Pathogenic
0.82
D
PROVEAN
Benign
-0.47
N
REVEL
Benign
0.28
Sift
Benign
0.14
T
Sift4G
Benign
0.62
T
Polyphen
0.019
B
Vest4
0.12
MPC
0.31
ClinPred
0.042
T
GERP RS
3.5
PromoterAI
0.064
Neutral
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.0
gMVP
0.37
Mutation Taster
=98/2
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs187930476; hg19: chr6-146056472; COSMIC: COSV107474609; COSMIC: COSV107474609; API